RT Journal Article
T1 Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
A1 Calderón-Goercke, Mónica
A1 Loricera, Javier
A1 Aldasoro, Vicente
A1 Castañeda, Santos
A1 Villa, Ignacio
A1 Humbría, Alicia
A1 Moriano, Clara
A1 Romero-Yuste, Susana
A1 Narváez, Javier
A1 Gómez-Arango, Catalina
A1 Pérez-Pampín, Eva
A1 Melero, Rafael
A1 Becerra-Fernández, Elena
A1 Revenga, Marcelino
A1 Álvarez-Rivas, Noelia
A1 Galisteo, Carles
A1 Sivera, Francisca
A1 Olivé-Marqués, Alejandro
A1 Álvarez Del Buergo, María
A1 Marena-Rojas, Luisa
A1 Fernández-López, Carlos
A1 Navarro, Francisco
A1 Raya, Enrique
A1 Galindez-Agirregoikoa, Eva
A1 Arca, Beatriz
A1 Solans-Laqué, Roser
A1 Conesa, Arantxa
A1 Hidalgo, Cristina
A1 Vázquez, Carlos
A1 Román-Ivorra, José Andrés
A1 Lluch, Pau
A1 Manrique-Arija, Sara
A1 Vela, Paloma
A1 De Miguel, Eugenio
A1 Torres-Martín, Carmen
A1 Nieto, Juan Carlos
A1 Ordas-Calvo, Carmen
A1 Salgado-Pérez, Eva
A1 Luna-Gomez, Cristina
A1 Toyos-Sáenz de Miera, F Javier
A1 Fernández-Llanio, Nagore
A1 García, Antonio
A1 Larena, Carmen
A1 Palmou-Fontana, Natalia
A1 Calvo-Río, Vanesa
A1 Prieto-Peña, Diana
A1 González-Vela, Carmen
A1 Corrales, Alfonso
A1 Varela-García, María
A1 Aurrecoechea, Elena
A1 Dos Santos, Raquel
A1 García-Manzanares, Ángel
A1 Ortego, Norberto
A1 Fernández, Sabela
A1 Ortiz-Sanjuán, Francisco
A1 Corteguera, Montserrat
A1 Hernández, José L
A1 González-Gay, Miguel Á
A1 Blanco, Ricardo
K1 Biological therapy
K1 Giant cell arteritis
K1 Large-vessel vasculitis
K1 Tocilizumab
AB Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice Methods: Observational, open-label multicenter study from 40 national referral centers of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants, glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was performed: (a) TCZ route (SC vs. IV); (b) GCA duration (≤6 vs. >6 months); (c) serious infections (with or without); (d) ≤15 vs. >15 mg/day at TCZ onset. 134 patients; mean age, 73.0 ± 8.8 years. TCZ was started after a median [IQR] time from GCA diagnosis of 13.5 [5.0-33.5] months. Ninety-eight (73.1%) patients had received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical improvement. Reduction of CRP from 1.7 [0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p  In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA. Serious infections appear to be higher than in clinical trials.
YR 2019
FD 2019-01-05
LK http://hdl.handle.net/10668/13431
UL http://hdl.handle.net/10668/13431
LA en
DS RISalud
RD Apr 16, 2025